UBS Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-56,930
| Closed | -$2.14M | – | 10384 |
|
|
2021
Q1 | $2.14M | Buy |
56,930
+50,932
| +849% | +$1.27M | ﹤0.01% | 3494 |
|
|
2020
Q4 | $102K | Buy |
5,998
+1,768
| +42% | +$22.2K | ﹤0.01% | 5677 |
|
|
2020
Q3 | $19K | Sell |
4,230
-54,317
| -93% | -$276K | ﹤0.01% | 6373 |
|
|
2020
Q2 | $357K | Buy |
58,547
+37,531
| +179% | +$155K | ﹤0.01% | 4391 |
|
|
2020
Q1 | $48K | Sell |
21,016
-29,990
| -59% | -$127K | ﹤0.01% | 5870 |
|
|
2019
Q4 | $234K | Sell |
51,006
-68,207
| -57% | -$270K | ﹤0.01% | 5500 |
|
|
2019
Q3 | $462K | Buy |
119,213
+117,135
| +5,637% | +$643K | ﹤0.01% | 4632 |
|
|
2019
Q2 | $12K | Sell |
2,078
-776
| -27% | -$7.42K | ﹤0.01% | 6979 |
|
|
2019
Q1 | $39K | Sell |
2,854
-96,584
| -97% | -$1.1M | ﹤0.01% | 5742 |
|
|
2018
Q4 | $925K | Buy |
99,438
+90,954
| +1,072% | +$1.08M | ﹤0.01% | 3747 |
|
|
2018
Q3 | $118K | Buy |
8,484
+1,927
| +29% | +$28.7K | ﹤0.01% | 5455 |
|
|
2018
Q2 | $104K | Sell |
6,557
-92,096
| -93% | -$1.61M | ﹤0.01% | 5415 |
|
|
2018
Q1 | $1.7M | Buy |
98,653
+87,363
| +774% | +$1.7M | ﹤0.01% | 3276 |
|
|
2017
Q4 | $248K | Buy |
11,290
+4,126
| +58% | +$133K | ﹤0.01% | 4768 |
|
|
2017
Q3 | $293K | Sell |
7,164
-512
| -7% | -$16.1K | ﹤0.01% | 4586 |
|
|
2017
Q2 | $231K | Buy |
7,676
+1,604
| +26% | +$50.1K | ﹤0.01% | 4661 |
|
|
2017
Q1 | $220K | Sell |
6,072
-15,986
| -72% | -$705K | ﹤0.01% | 4600 |
|
|
2016
Q4 | $1.1M | Buy |
22,058
+7,170
| +48% | +$377K | ﹤0.01% | 3464 |
|
|
2016
Q3 | $782K | Buy |
14,888
+13,086
| +726% | +$625K | ﹤0.01% | 3597 |
|
|
2016
Q2 | $75K | Buy |
1,802
+987
| +121% | +$42.9K | ﹤0.01% | 5231 |
|
|
2016
Q1 | $33K | Sell |
815
-61
| -7% | -$2.1K | ﹤0.01% | 5819 |
|
|
2015
Q4 | $37K | Buy |
+876
| New | +$29.4K | ﹤0.01% | 6127 |
|
|
2015
Q3 | – | Sell |
-898
| Closed | -$22K | – | 8762 |
|
|
2015
Q2 | $22K | Buy |
+898
| New | +$20K | ﹤0.01% | 6794 |
|
UBS Group's FPRX Position: Q2 2021 in Review
UBS Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 56,930 shares — an estimated $2.14M sold.
UBS Group first reported a position in FPRX in Q2 2015 and held it in 23 quarters. The position peaked at $2.14M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- UBS Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- UBS Group sold 56,930 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $2.14M.
- UBS Group first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 23 quarters.
- UBS Group's Five Prime Therapeutics, Inc. position peaked at $2.14M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.